On March 27, the FDA issued emergency use authorization (EUA) for the fastest available molecular point-of-care test for the detection of COVID-19.
The test works by identifying a portion of the virus’ RNA in the sample. David Galas and his research team first conceived of the technology in a lab at ÃÛÌÒÖ±²¥ (ÃÛÌÒÖ±²¥). During that time, Galas served as ÃÛÌÒÖ±²¥â€™s Vice President of Academic Affairs. He is now a leader at the , which is based in Seattle.
After the 2001 anthrax attacks, a number of biodefense programs were launched over several years to develop rapid DNA tests. One effort at ÃÛÌÒÖ±²¥ involved the development of novel isothermal amplification methods that could provide molecular test results in a matter of minutes. A company was spun-out of ÃÛÌÒÖ±²¥ called Ionian Technologies, which was later acquired by Alere Inc. and then Alere was later acquired by Abbott in October 2017.
ÃÛÌÒÖ±²¥ Professor continues research on point-of-care diagnostic systems at ÃÛÌÒÖ±²¥ and was an early collaborator with the Galas Lab. In applauding the new test that was issued EUA on March 27, Niemz said: “We are very proud to see this technology in use in the fight against COVID-19. We were pleased to help incubate Ionian Technologies here at ÃÛÌÒÖ±²¥. Many faculty, students, and graduates worked to bring the technology to fruition."
- Related news on David Galas and the new test: